Printer Friendly

PHARMAKINETICS LABORATORIES CHANGE IN CERTIFYING ACCOUNTANTS

 PHARMAKINETICS LABORATORIES CHANGE IN CERTIFYING ACCOUNTANTS
 BALTIMORE, Feb. 3 /PRNewswire/ -- PharmaKinetics Laboratories, Inc. (NASDAQ: PKLBQ) today reported a change in the engagement of its certifying accountants. For the year ending June 30, 1992, the company has appointed Coopers & Lybrand, independent certified public accountants, as its independent auditors. Deloitte & Touche had been the company's independent auditor for the years ended June 30, 1983- 1991.
 During the company's two most recent fiscal years and any subsequent interim period preceding such replacement, to the knowledge of new management, there were no disagreements with Deloitte & Touche on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Deloitte & Touche, would have caused it to make reference to the subject matter of the disagreements in connection with its reports.
 PharmaKinetics Laboratories, Inc. is a leading drug development company providing services to pharmaceutical and biotechnology firms seeking new drug approvals in the United States and Europe.
 -0- 2/3/92
 /CONTACT: Taryn L. Kunkel, vice president and chief financial officer of PharmaKinetics, 410-385-4500/
 (PKLBQ) CO: PharmaKinetics Laboratories, Inc.; Coopers & Lybrand ST: Maryland IN: MTC SU:


MK -- DC006 -- 6017 02/03/92 09:13 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 3, 1992
Words:202
Previous Article:'HALFPRIN' NEW LOW STRENGTH ADULT ASPIRIN INTRODUCED BY KRAMER LABORATORIES
Next Article:TAMBRANDS ANNOUNCES 1991 RESULTS
Topics:


Related Articles
PHARMAKINETICS LABORATORIES, INC., ANNOUNCES ITS COMMON STOCK DELISTED FROM NASDAQ TRADING SYSTEM
PHARMAKINETICS LABORATORIES, INC., ANNOUNCES PROPOSED SALE OF GERMAN SUBSIDIARY
PHARMAKINETICS LABORATORIES, INC., ANNOUNCES THIRD QUARTER EARNINGS
PHARMAKINETICS LABORATORIES, INC., RELEASES FIRST QUARTER RESULTS
PHARMAKINETICS LABORATORIES, INC., ANNOUNCES APPOINTMENT OF VICE PRESIDENT FOR CLINICAL EVALUATION SERVICES
PHARMAKINETICS LABORATORIES REPORTS RECEIPT OF WARNING LETTER FROM FDA
PHARMAKINETICS LABORATORIES, INC. ANNOUNCES JOINT PROJECT WITH THE UNIVERSITY OF MARYLAND AT BALTIMORE
PHARMAKINETICS LABORATORIES, INC. ANNOUNCES FIRST QUARTER EARNINGS
PHARMAKINETICS LABORATORIES, INC. ANNOUNCES NEW CHIEF EXECUTIVE OFFICER
PHARMAKINETICS LABORATORIES, INC. ANNOUNCES FIRST QUARTER EARNINGS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters